Used in targeted cancer therapy, particularly for hepatocellular carcinoma (HCC). Binds specifically to Glypican-3 (GPC3), a protein overexpressed in liver cancer cells but minimal in healthy tissue. This selective binding allows delivery of the cytotoxic agent MMAE directly to tumor cells. Upon internalization, MMAE disrupts microtubule networks, leading to cell cycle arrest and apoptosis. Enables precise tumor targeting with reduced damage to normal cells, making it a promising approach in antibody-drug conjugate (ADC) treatments for advanced liver cancer.